What are the causes of hypercalcemia and hyperuricemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Causes of Hypercalcemia and Hyperuricemia

Hypercalcemia Causes

The differential diagnosis of hypercalcemia is fundamentally organized by PTH level, which distinguishes between PTH-dependent and PTH-independent etiologies 1.

PTH-Elevated or Inappropriately Normal Hypercalcemia

  • Primary hyperparathyroidism (PHPT) - accounts for approximately 90% of hypercalcemia cases in outpatients 2
  • Familial hypocalciuric hypercalcemia (FHH) - caused by inactivating mutations in CASR, GNA11, or AP2S1 genes 1
  • Malignancy with PTH-rP secretion - common in epidermoid and neuroendocrine tumors, causes humoral hypercalcemia of cancer with characteristic renal hypophosphatemia 1

PTH-Suppressed or Low Hypercalcemia (6 Main Categories) 1

Malignant causes:

  • Osteolytic metastases from solid tumors (breast cancer) or multiple myeloma - typically accompanied by hyperphosphatemia 1
  • Local osteolysis via NFKappaB-RANK-ligand pathway 1

Hypervitaminosis D:

  • Excessive calcitriol production by granulomatous tissue or macrophages via extra-renal 1-alpha-hydroxylase in granulomatosis, lymphoma, or pneumocystosis 1
  • May present with elevated phosphatemia due to increased intestinal phosphate absorption 1

Genetic causes:

  • Childhood idiopathic hypercalcemia type 1 (CYP24A1 gene variants) 1
  • Mahvash syndrome (GCGR gene variants) 1
  • Williams-Beuren syndrome (chromosome 7 microdeletion) - 15% develop moderate infantile hypercalcemia 1
  • Jansen's metaphyseal chondrodysplasia (activating PTH1R variants) 1
  • Hypophosphatasia (ALPL gene mutation with low alkaline phosphatase) 1

Immobilization-related:

  • Occurs 4-6 weeks after immobilization in young adults post-spinal trauma or elderly poly-pathological patients
  • Mediated by increased sclerostin inhibiting Wnt pathway, causing preponderance of osteoclastic resorption 1

Endocrine causes:

  • Hyperthyroidism - direct thyroid hormone action on bone resorption 1
  • Acute adrenal insufficiency - hypercalcemia typically <3 mmol/L from dehydration and metabolic acidosis 1
  • Pheochromocytoma - direct catecholamine action on bone or PTH-rP secretion 1
  • Acromegaly - hypercalcemic tendency from increased calcitriol production via IGF-1 action 1

Drug-induced:

  • Thiazide diuretics, lithium, excessive vitamin D or calcium supplementation 1, 2
  • Immune checkpoint inhibitors, denosumab discontinuation 2

Other causes:

  • Cirrhosis (chronic or acute decompensation) - linked to inflammatory cytokines and prostaglandins, associated with increased mortality 1

Critical Diagnostic Algorithm

First, measure PTH:

  • Elevated/normal PTH → PHPT or FHH (check calciuria, genetic testing)
  • Suppressed PTH (<20 pg/mL) → evaluate for malignancy, vitamin D excess, endocrinopathies, drugs, immobilization 2

Common pitfall: Calciuria alone cannot reliably distinguish FHH from PHPT due to overlapping ranges 1. FHH subjects have normal calciuria, not truly "hypocalciuric" 1.


Hyperuricemia Causes

Hyperuricemia is defined as serum urate >6.8-7.0 mg/dL and results from either uric acid overproduction or underexcretion 3.

Primary Causes

  • Idiopathic hyperuricemia - most common, often associated with metabolic syndrome 3
  • Genetic disorders - enzyme defects affecting purine metabolism

Secondary Causes

Increased uric acid production:

  • Myeloproliferative disorders
  • Lymphoproliferative disorders
  • Hemolytic anemias
  • Psoriasis
  • High purine diet (red meat, seafood, alcohol especially beer)

Decreased uric acid excretion:

  • Chronic kidney disease - most important cause of reduced excretion 3, 4
  • Medications: thiazide and loop diuretics (most common drug cause), low-dose aspirin 3
  • Hypertension 3, 4
  • Metabolic syndrome and obesity 3
  • Type 2 diabetes 3
  • Lead nephropathy
  • Lactic acidosis
  • Ketoacidosis

Cardiovascular Risk Context

Elevated serum uric acid is independently associated with cardiovascular mortality, heart failure, stroke, and faster CKD progression 4. However, routine urate-lowering therapy for asymptomatic hyperuricemia has not shown clear cardiovascular benefit in randomized trials 4.

Management Threshold

For symptomatic gout or very high cardiovascular risk, target serum urate 180-300 μmol/L (3-5 mg/dL) with febuxostat as first-line therapy 5. ULT should be customized according to pathophysiologic type (overproduction vs. underexcretion) 5.

Key distinction: Asymptomatic hyperuricemia requires risk stratification before treatment, whereas gout with tophi or recurrent flares mandates urate-lowering therapy 3, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.